{"id":71650,"date":"2026-08-04T16:02:56","date_gmt":"2026-08-04T08:02:56","guid":{"rendered":"https:\/\/flcube.com\/?p=71650"},"modified":"2026-08-04T16:02:58","modified_gmt":"2026-08-04T08:02:58","slug":"zai-labs-zocilurtatug-pelitecan-receives-fda-orphan-drug-designation-for-neuroendocrine-carcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71650","title":{"rendered":"Zai Lab’s Zocilurtatug Pelitecan Receives FDA Orphan Drug Designation for Neuroendocrine Carcinoma"},"content":{"rendered":"\n

Zai Lab<\/strong> (NASDAQ: ZLAB<\/a>; HKG: 9688<\/a>) announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD)<\/strong> to zocilurtatug pelitecan (zoci<\/strong>, formerly known as ZL-1310) for the treatment of neuroendocrine carcinoma (NEC)<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Zai Lab (NASDAQ: ZLAB; HKG: 9688)<\/td><\/tr>
Product<\/strong><\/td>Zocilurtatug pelitecan (zoci, formerly ZL-1310)<\/td><\/tr>
Regulatory Status<\/strong><\/td>FDA Orphan Drug Designation (ODD)<\/td><\/tr>
Indication<\/strong><\/td>Neuroendocrine carcinoma (NEC)<\/td><\/tr>
Announcement Date<\/strong><\/td>3 Aug 2026<\/td><\/tr>
Product Type<\/strong><\/td>Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC) with first-in-class potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Previous Regulatory Designations<\/h2>\n\n\n\n